Kenneth Zuerblis
Vermogen: 34 203 $ op 31-05-2026
Vermogen: 34 203 $ op 31-05-2026
Mr. Kenneth J.
Zuerblis, CPA, is an Independent Director at Zenith Capital Corp.
(Alberta) and an Independent Director at Resverlogix Corp.
He is on the Board of Directors at Lirum Therapeutics, Inc., Zenith Capital Corp.
(Alberta) and Resverlogix Corp.
Mr. Zuerblis was previously employed as a Chief Financial Officer, Treasurer & Executive VP by Savient Pharmaceuticals, Inc., an Independent Director by Immunomedics, Inc., a Chief Financial Officer & Senior Vice President by ImClone Systems, Inc., a Chief Financial Officer by Enzon Pharmaceuticals, Inc., and a Controller by KPMG LLP.
He also served on the board at Stemline Therapeutics, Inc., XTL Biopharmaceuticals Ltd. and New Jersey Technology Council.
He received his undergraduate degree from Seton Hall University.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
ZENITH CAPITAL CORP. 0,17% | 19-05-2026 | 263.870 ( 0,17% ) | 26 387 $ | 31-01-2026 |
RESVERLOGIX CORP. 0,03% | 02-01-2026 | 107.062 ( 0,03% ) | 7 816 $ | 31-05-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| RESVERLOGIX CORP. | Directeur/Bestuurslid | 29-09-2010 |
| ZENITH CAPITAL CORP. | Directeur/Bestuurslid | 10-04-2013 |
| LIRUM THERAPEUTICS, INC. | Directeur/Bestuurslid | 01-05-2023 |
| Bedrijven | Functie | Einde |
|---|---|---|
| STEMLINE THERAPEUTICS, INC. | Directeur/Bestuurslid | 10-06-2020 |
| SAVIENT PHARMACEUTICALS INC | Financieel Directeur/CFO | 01-05-2012 |
| IMMUNOMEDICS, INC. | Directeur/Bestuurslid | 08-03-2012 |
ImClone LLC
ImClone LLC BiotechnologyHealth Technology Develops novel therapeutic products and blood cell growth factors for the treatment of cancer | Financieel Directeur/CFO | 01-01-2009 |
| XTL BIOPHARMACEUTICALS LTD. | Directeur/Bestuurslid | 01-01-2009 |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 12 |
|---|---|
Savient Pharmaceuticals, Inc.
Savient Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a specialty biopharmaceutical company, which develops, manufactures and markets pharmaceutical products | Health Technology |
Enzon Pharmaceuticals, Inc.
Enzon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops innovative therapeutics for cancer patients | Health Technology |
ImClone LLC
ImClone LLC BiotechnologyHealth Technology Develops novel therapeutic products and blood cell growth factors for the treatment of cancer | Health Technology |
Immunomedics, Inc.
Immunomedics, Inc. BiotechnologyHealth Technology Develops drugs for the treatment of cancer | Health Technology |
Resverlogix Corp.
Resverlogix Corp. Pharmaceuticals: MajorHealth Technology Engages in the research and development of novel biopharmaceuticals for the treatment of grievous diseases | Health Technology |
Stemline Therapeutics, Inc.
Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel oncology therapeutics | Health Technology |
Zenith Capital Corp. (Alberta)
Zenith Capital Corp. (Alberta) BiotechnologyHealth Technology Engages in the research and development of biopharmaceuticals | Health Technology |
KPMG LLP
KPMG LLP Miscellaneous Commercial ServicesCommercial Services Provides auditing, tax and advisory services | Commercial Services |
XTL Biopharmaceuticals Ltd.
XTL Biopharmaceuticals Ltd. Medical SpecialtiesHealth Technology Develops pharmaceutical drugs for the treatment of autoimmune diseases | Health Technology |
Seton Hall University
Seton Hall University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
New Jersey Technology Council
New Jersey Technology Council Miscellaneous Commercial ServicesCommercial Services Provides business development, education and advocacy services | Commercial Services |
Lirum Therapeutics, Inc.
Lirum Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that focuses on the treatment of debilitating diseases | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau